Meeting Banner
Abstract #3167

The IASLC/ ITMIG Thymic Epithelial Tumor Staging: Comparison of Staging Capability among Whole-Body PET/MRI, MRI including DWI, PET/CT and Conventional Radiological Examination

Yoshiharu Ohno1,2, Yuji Kishida3, Sinichiro Seki1,2, Kota Aoyagi4, Masao Yui4, Yoshimori Kassai5, Wakiko Tani6, Noriyuki Negi6, Katsusuke Kyotani6, and Takeshi Yoshikawa1,2

1Division of Functional and Diagnostic Imaging Research, Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Advanced Biomedical Imaging Research Center, Kobe University Graduate School of Medicine, Kobe, Japan, 3Division of Radiology, Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan, 4Center for Medical Research and Development, Toshiba Medical Systems Corporation, Otawara, Japan, 5MR Clinical Solution department, Toshiba Medical Systems Corporation, Otawara, Japan, 6Center for Radiology and Radiation Oncology, Kobe University Hospital, Kobe, Japan

Accurate stage assessment is essential for choosing the appropriate treatment strategy for thymic epithelial tumor patients. Recently, the International Association for the Study of Lung Cancer (IASLC) and International Thymic Malignancies Interest Group (ITMIG) proposed a new IASLC/ITMIG thymic epithelial tumor stage classification system. The purpose of this study was to compare the diagnostic capability for the IASLC/ ITMIG thymic epithelial tumor staging among whole-body FDG-PET/MRI, MRI, FDG-PET/CT and conventional radiological examinations based on guidelines.

This abstract and the presentation materials are available to members only; a login is required.

Join Here